Pfizer Releases Positive Preliminary Data on Vaccine, Must Commit to Affordable Pricing
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Monday reacting to preliminary data released by Pfizer Inc. on the efficacy of the company’s COVID-19 vaccine.
“Any COVID-19 treatments and vaccines that ultimately come to market must be priced responsibly so they are accessible and affordable for all Americans,” said CSRxP executive director Lauren Aronson. “While Pfizer’s vaccine announcement reflects only preliminary data, the company should commit now to affordable pricing and policymakers must be prepared to hold Big Pharma accountable if companies try to price-gouge these products.”
Read more on how Pfizer hiked prescription drug prices 124 times this year, including in July at the height of the pandemic crisis, to boost the company’s bottom line HERE.
Read how another Big Pharma company, Gilead, is already price-gouging a COVID-19 treatment HERE.
Read more on market-based solutions to hold Big Pharma accountable HERE.